Logo image of ADIL

ADIAL PHARMACEUTICALS INC (ADIL) Stock Fundamental Analysis

USA - NASDAQ:ADIL - US00688A2050 - Common Stock

0.3567 USD
+0.01 (+1.86%)
Last: 10/30/2025, 8:00:00 PM
0.3479 USD
-0.01 (-2.47%)
After Hours: 10/30/2025, 8:00:00 PM
Fundamental Rating

2

Overall ADIL gets a fundamental rating of 2 out of 10. We evaluated ADIL against 192 industry peers in the Pharmaceuticals industry. The financial health of ADIL is average, but there are quite some concerns on its profitability. ADIL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ADIL has reported negative net income.
ADIL had a negative operating cash flow in the past year.
ADIL had negative earnings in each of the past 5 years.
In the past 5 years ADIL always reported negative operating cash flow.
ADIL Yearly Net Income VS EBIT VS OCF VS FCFADIL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of ADIL (-124.23%) is worse than 80.21% of its industry peers.
ADIL has a Return On Equity of -151.14%. This is in the lower half of the industry: ADIL underperforms 68.23% of its industry peers.
Industry RankSector Rank
ROA -124.23%
ROE -151.14%
ROIC N/A
ROA(3y)-197.33%
ROA(5y)-210.06%
ROE(3y)-279.33%
ROE(5y)-332.84%
ROIC(3y)N/A
ROIC(5y)N/A
ADIL Yearly ROA, ROE, ROICADIL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

ADIL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADIL Yearly Profit, Operating, Gross MarginsADIL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, ADIL has more shares outstanding
ADIL has more shares outstanding than it did 5 years ago.
ADIL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ADIL Yearly Shares OutstandingADIL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ADIL Yearly Total Debt VS Total AssetsADIL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -17.05, we must say that ADIL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -17.05, ADIL is not doing good in the industry: 79.69% of the companies in the same industry are doing better.
ADIL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.05
ROIC/WACCN/A
WACCN/A
ADIL Yearly LT Debt VS Equity VS FCFADIL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 5.02 indicates that ADIL has no problem at all paying its short term obligations.
ADIL's Current ratio of 5.02 is fine compared to the rest of the industry. ADIL outperforms 69.27% of its industry peers.
ADIL has a Quick Ratio of 5.02. This indicates that ADIL is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 5.02, ADIL is doing good in the industry, outperforming 69.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.02
Quick Ratio 5.02
ADIL Yearly Current Assets VS Current LiabilitesADIL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

1

3. Growth

3.1 Past

ADIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.58%, which is quite impressive.
EPS 1Y (TTM)66.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ADIL will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.53% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y66.18%
EPS Next 2Y30.09%
EPS Next 3Y18.11%
EPS Next 5Y8.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADIL Yearly Revenue VS EstimatesADIL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 50M 100M 150M
ADIL Yearly EPS VS EstimatesADIL Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADIL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ADIL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADIL Price Earnings VS Forward Price EarningsADIL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADIL Per share dataADIL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ADIL's earnings are expected to grow with 18.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.09%
EPS Next 3Y18.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADIL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADIAL PHARMACEUTICALS INC

NASDAQ:ADIL (10/30/2025, 8:00:00 PM)

After market: 0.3479 -0.01 (-2.47%)

0.3567

+0.01 (+1.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners2.62%
Inst Owner Change0%
Ins Owners0.39%
Ins Owner Change0%
Market Cap7.79M
Revenue(TTM)N/A
Net Income(TTM)-8450000
Analysts82.22
Price Target2.55 (614.89%)
Short Float %2.1%
Short Ratio0.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.04%
Min EPS beat(2)29.41%
Max EPS beat(2)32.66%
EPS beat(4)4
Avg EPS beat(4)21.78%
Min EPS beat(4)9.7%
Max EPS beat(4)32.66%
EPS beat(8)4
Avg EPS beat(8)-10.16%
EPS beat(12)8
Avg EPS beat(12)13.93%
EPS beat(16)10
Avg EPS beat(16)9.54%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-37.5%
EPS NQ rev (1m)-2.44%
EPS NQ rev (3m)24.32%
EPS NY rev (1m)-22.54%
EPS NY rev (3m)27.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.39
P/tB 1.39
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0
BVpS0.26
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -124.23%
ROE -151.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-197.33%
ROA(5y)-210.06%
ROE(3y)-279.33%
ROE(5y)-332.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.02
Quick Ratio 5.02
Altman-Z -17.05
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.49%
EPS Next Y66.18%
EPS Next 2Y30.09%
EPS Next 3Y18.11%
EPS Next 5Y8.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.67%
OCF growth 3YN/A
OCF growth 5YN/A

ADIAL PHARMACEUTICALS INC / ADIL FAQ

What is the fundamental rating for ADIL stock?

ChartMill assigns a fundamental rating of 2 / 10 to ADIL.


What is the valuation status of ADIAL PHARMACEUTICALS INC (ADIL) stock?

ChartMill assigns a valuation rating of 0 / 10 to ADIAL PHARMACEUTICALS INC (ADIL). This can be considered as Overvalued.


How profitable is ADIAL PHARMACEUTICALS INC (ADIL) stock?

ADIAL PHARMACEUTICALS INC (ADIL) has a profitability rating of 0 / 10.


Can you provide the financial health for ADIL stock?

The financial health rating of ADIAL PHARMACEUTICALS INC (ADIL) is 6 / 10.